# Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635--c021b8ab
Ticker: SRPT
Company: Sarepta Therapeutics
Source: Sarepta Therapeutics
Published: 2026-06-30 20:25 EST
Original Source URL: https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-inducement-grants-under-112
## Summary

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 30, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024

## Article Body
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 30, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024
## Recent Company News
- 2026-06-30 20:25 EST — [Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635--c021b8ab) — Source: Sarepta Therapeutics
- 2026-06-30 12:30 EST — [Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®](https://biopharmsignal.com/news/SRPT/sarepta-announces-fda-acceptance-of-sndas-for-amondys-45-and-vyondys-53-40aea7f9) — Source: Sarepta Therapeutics
- 2026-06-25 13:46 EST — [Sarepta Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-to-participate-in-upcoming-investor-conferences) — Source: Sarepta Therapeutics
- 2026-06-25 13:46 EST — [Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference](https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference) — Source: Sarepta Therapeutics
- 2026-06-25 13:46 EST — [Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments](https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-announces-first-quarter-2026-financial-results-and-recent-corporate-developments) — Source: Sarepta Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)